Jason Shirian
YOU?
Author Swipe
View article: Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension Open
Matrix metalloproteinases (MMPs) are significant drivers of many diseases, including cancer, and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors and are being purs…
View article: Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension
Improving Circulation Half-Life of Therapeutic Candidate N-TIMP2 by Unfolded Peptide Extension Open
Matrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are being pursued for…
View article: Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein–Protein Complexes
Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein–Protein Complexes Open
Protein-protein interactions (PPIs) have evolved to display binding affinities that can support their function. As such, cognate and noncognate PPIs could be highly similar structurally but exhibit huge differences in binding affinities. T…
View article: Climbing up and down binding landscapes: a high-throughput study of mutational effects in homologous protein-protein complexes
Climbing up and down binding landscapes: a high-throughput study of mutational effects in homologous protein-protein complexes Open
Each protein-protein interaction (PPI) has evolved to possess binding affinity that is compatible with its cellular function. As such, cognate enzyme/inhibitor interactions frequently exhibit very high binding affinities, while structurall…
View article: Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of <scp>MMP</scp> ‐9 and <scp>MMP</scp> ‐14
Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of <span>MMP</span> ‐9 and <span>MMP</span> ‐14 Open
MMP ‐14 and MMP ‐9 are two well‐established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an i…
View article: Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14
Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14 Open
MMP-14 and MMP-9 are two well established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inh…